Pharmalive -- COPENHAGEN, 24 August 2010 – Today, NeuroSearch A/S (NEUR), a leading CNS focused and European based biopharmaceutical company announced the appointment of Patrik Dahlen as new CEO of the company. With effect from 15 September 2010, Patrik Dahlen will replace CEO Flemming Pedersen, who resigns to take up a new position in another company.
